Latest approaches for the treatment of obesity
| Autor: | Bhavik P. Shah, Jean-Philippe Fortin, Alice Liou, A. Katrina Loomis, J. Brent Kuzmiski, Philip A. Carpino, V. Margaret Jackson, Marie-Laure Rives, Danna M. Breen |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
FGF21
Drug discovery Critical pathways Type 2 diabetes Biology Pharmacology Bioinformatics Body weight medicine.disease Obesity Energy homeostasis Weight loss Drug Design Drug Discovery Weight Loss medicine Animals Humans Drug Therapy Combination Anti-Obesity Agents Molecular Targeted Therapy medicine.symptom |
| Zdroj: | Expert opinion on drug discovery. 10(8) |
| ISSN: | 1746-045X |
| Popis: | Obesity is a body weight disorder characterized by excess adiposity that increases the risk for developing co-morbidities such as type 2 diabetes. A large medical need exists for new anti-obesity treatments capable of promoting 10% or greater weight loss, with minimal side effects.The authors describe the application of monogenic forms of rare obesity and genome-wide association studies in selecting critical pathways for drug discovery. Furthermore, they review in detail several pathways and pharmacological targets in the central nervous system (e.g., the leptin-melanocortin axis, the opioid system, GLP-1/GLP-1 system, and FGF21/FGFR1c/β-Klotho axis) that play an important role in the regulation of feeding behavior and energy homeostasis. Special focus is given to new strategies that engage well-known targets via novel mechanisms in order to circumvent issues seen with previous drug candidates that failed in the clinic. Finally, the authors discuss the recent developments around fixed-dose combinations, targeted polypharmacology, and non-traditional combinations of drugs and devices.The future for new weight-loss approaches to treat obesity looks promising. Current therapies have shown modest effects on weight loss in the general obese population but will have greater impact in smaller homogeneous sub-populations of obese subjects using personalized medicine. Drug combinations that target multiple, complementary pathways have the potential to promote double-digit weight loss in a broader, heterogeneous patient population. Furthermore, the development of advanced subcutaneous delivery technologies has opened up opportunities to develop breakthrough peptide and biologic agents for the treatment of obesity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|